Tay-Sachs Disease – Epidemiology – Mature Markets
DRG Epidemiology’s coverage of Tay-Sachs disease comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of Tay-Sachs disease for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
DRG Epidemiology’s Tay-Sachs disease forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of Tay-Sachs disease over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following Tay-Sachs disease patient populations:
Diagnosed prevalence of Tay-Sachs disease.
Table of contents
- Tay-Sachs Disease - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Diagnosed Prevalence of Tay-Sachs Disease per 100,000 People of All Ages in 2019 and 2039
- Epidemiology Data
- Methods
- Diagnosed Prevalent Cases of Tay-Sachs Disease (Infantile-Onset)
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Tay-Sachs Disease (Infantile-Onset)
- Studies Excluded from the Analysis of Tay-Sachs Disease (Infantile-Onset)
- Risk/Protective Factors
- Risk/Protective Factors for Tay-Sachs Disease
- Bibliography
- Literature Review
- Introduction
Shilpa Thakur, M.P.H., is an epidemiologist at Clarivate. Previously, she monitored HIV sentinel surveillance in Himachal Pradesh. She has also studied the patterns of antimicrobial resistance in India. She received her M.P.H. from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics.
Abey John, M.P.H., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, he worked with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing family planning health programs in India in collaboration with the government of India. He also has worked at the grassroots level as a health team manager to help the rural population living in the foothills of the Himalayas. He holds a master’s degree in public health.